SG Americas Securities
TBIO

SG Americas Securities’s Translate Bio, Inc. Common Stock TBIO Stock Holding History

SG Americas Securities’s Portfolio TBIO Stock Details TBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-44,989
Closed -$1.24M – 3936
2021
Q2 		$1.24M Buy
44,989
+6,241
+16% +$123K 0.01% 1421
2021
Q1 		$639K Buy
38,748
+15,200
+65% +$346K ﹤0.01% 1845
2020
Q4 		$434K Sell
23,548
-40,280
-63% -$721K ﹤0.01% 2082
2020
Q3 		$869K Buy
63,828
+46,985
+279% +$724K 0.01% 1272
2020
Q2 		$302K Buy
16,843
+2,846
+20% +$42.9K ﹤0.01% 2518
2020
Q1 		$140K Buy
+13,997
New +$115K ﹤0.01% 2759

SG Americas Securities's TBIO Position: Q3 2021 in Review

SG Americas Securities sold out of Translate Bio, Inc. Common Stock (TBIO) in Q3 2021, closing a stake of 44,989 shares — an estimated $1.24M sold.

SG Americas Securities first reported a position in TBIO in Q1 2020 and held it in 6 quarters. The position peaked at $1.24M in Q2 2021. 0 funds tracked by Wall St. Rank hold TBIO as of Q3 2021.

  • SG Americas Securities reported no remaining Translate Bio, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • SG Americas Securities sold 44,989 Translate Bio, Inc. Common Stock shares in Q3 2021, an estimated $1.24M.
  • SG Americas Securities first reported a position in Translate Bio, Inc. Common Stock in Q1 2020 and held it in 6 quarters.
  • SG Americas Securities's Translate Bio, Inc. Common Stock position peaked at $1.24M in Q2 2021.
  • 0 funds tracked by Wall St. Rank held Translate Bio, Inc. Common Stock as of Q3 2021.

Based on SG Americas Securities's 13F filing for Q3 2021, filed 1 Nov 2021.